Highest-materiality recent filing
Thermo Fisher say-on-pay fails with 68% votes against at 2026 annual meeting
All 11 director nominees elected; top vote-getter Debora L. Spar (314.4M for), lowest Dion J. Weisler (281.8M for).
Thermo Fisher Q1 revenue $11.01B (+6% YoY); adjusted EPS $5.44 (+6%)
Q1 revenue $11.01B, up 6% YoY; organic revenue growth 1%.
Thermo Fisher completes acquisition of Clario Holdings; no deal terms disclosed in filing
Acquisition of Clario Holdings, Inc. completed on March 24, 2026.
Thermo Fisher issues $3.8B in senior notes to partially fund Clario acquisition
Issued four tranches: $1B 4.215% Notes due 2031, $750M 4.550% due 2033, $1.3B 4.902% due 2036, $750M 5.546% due 2046.
Thermo Fisher Q4 rev $12.21B (+7%), adj EPS $6.57 (+8%); FY rev $44.56B (+4%)
Q4 GAAP diluted EPS $5.21 (+9%); adj EPS $6.57 (+8%); GAAP operating margin 18.5%.
Thermo Fisher EVP/COO Lagarde and EVP Lowery to depart; Pettiti promoted to President and COO
Michel Lagarde, EVP & COO, leaves March 31, 2026; Frederick Lowery, EVP, leaves Feb 28, 2026.
Thermo Fisher issues €2.1B in senior notes via finance subsidiary
Issued €1.0B floating-rate notes due 2027 and €1.1B 3.628% notes due 2035.
Thermo Fisher to acquire Clario Holdings for $8.875B; deal expected to close mid-2026
$8.875B cash at closing; additional $125M deferred and up to $400M contingent consideration.
Thermo Fisher Q3 revenue $11.12B (+5%); adjusted EPS $5.79 (+10%)
Revenue $11.12B, +5% reported and +3% organic; GAAP EPS $4.27 vs $4.25 YoY.
Thermo Fisher issues $2.5B senior notes in four tranches due 2031–2037
Issued $500M 4.200% notes due 2031, $750M 4.473% notes due 2032, $750M 4.794% notes due 2035, and $500M 4.894% notes due 2037.
Thermo Fisher completes acquisition of Solventum's purification and filtration business
Transaction closed as of September 2, 2025.
Thermo Fisher Q2: rev +3% to $10.85B, GAAP EPS $4.28 (+6%), adj EPS $5.36
Q2 revenue $10.85B (+3% YoY; organic 2%); GAAP diluted EPS $4.28, up 6% from $4.04.
Thermo Fisher CFO Stephen Williamson to retire March 2026; James Meyer named successor
CFO Stephen Williamson will retire effective March 31, 2026.
Thermo Fisher say-on-pay vote fails at 2025 annual meeting; all directors elected
Non-binding advisory vote on executive compensation failed: 201.4M against vs 111.1M for (64.5% against).
Thermo Fisher grants CEO Casper $60M performance RSU award with TSR-based vesting through 2030
Target award of 141,538 shares (~$60M) to CEO Marc Casper; cliff vesting May 21, 2030 contingent on TSR vs S&P 500.
Thermo Fisher Q1 GAAP EPS $3.98 (+15%), revenue $10.36B; agrees to acquire Solventum biz for $4.1B
Q1 revenue $10.36B (+0.2% YoY); organic growth 1%; GAAP diluted EPS $3.98 (+15%).
Thermo Fisher to acquire Solventum's purification and filtration business for $4.1B
Deal value approximately $4.1 billion in cash.
Thermo Fisher elects former CVS Health CEO Karen S. Lynch to its board
Board size increased to 12; Lynch elected effective February 19, 2025, term until 2025 annual meeting.
Thermo Fisher Q4 revenue $11.40B (+5%), adj. EPS $6.10 (+8%)
Q4 GAAP diluted EPS $4.78 (+14% YoY); adjusted EPS $6.10 (+8% YoY).
Thermo Fisher Q3 revenue flat at $10.60B; adjusted EPS $5.28; raises FY adjusted EPS guidance
Revenue $10.60B, essentially flat versus $10.57B in Q3 2023; organic revenue also flat.
Thermo Fisher Q2 GAAP EPS $4.04 (+15%), Adj. EPS $5.37 (+4%), raises FY 2024 guidance
Revenue $10.54B, down 1% YoY; organic revenue -1%, core organic revenue flat.
Thermo Fisher announces expiration and results of Olink tender offer
TMO subsidiary Orion Acquisition AB concluded tender offer for all Olink common shares and ADRs.
All 11 director nominees elected; highest votes for Debora L. Spar (318.2M for) and lowest for Marc N. Casper (291.6M for).
Thermo Fisher Q1 rev $10.34B (-3%), GAAP EPS $3.46 (+4%), raises FY guidance
GAAP diluted EPS $3.46 vs $3.32 YoY; adjusted EPS $5.11 vs $5.03 (+2%).
Q4 revenue $10.89B (-5% YoY), adjusted EPS $5.67 (+5%); guides 2024 revenue $42.1-43.3B
Q4 GAAP EPS $4.20 (+5% YoY); adjusted EPS $5.67 (+5%); GAAP operating margin 17.0% vs 16.3%.
Thermo Fisher issues $2.5B in senior notes; net proceeds ~$2.48B for general corporate purposes
Issued $1B of 5.000% notes due 2026, $1B of 5.000% notes due 2029, and $500M of 5.200% notes due 2034.
Thermo Fisher Scientific 401(k) blackout Dec 21 to Jan 14 due to plan admin transition
401(k) plan transitioning to a new administrator, causing temporary suspension of participant transactions.
Thermo Fisher Q3 revenue $10.57B (-1% YoY); GAAP EPS $4.42 (+17%); acquires Olink for ~$3.1B
Revenue $10.57B, down 1% YoY; core organic revenue grew 1%; COVID testing revenue $0.05B.
Thermo Fisher to acquire Olink for $26/share, ~$3.1B total
Cash tender offer at $26/ADS, ~74% premium to Oct 16 close; transaction values Olink at ~$3.1B including ~$143M net cash.
Thermo Fisher's new director Jenny Johnson appointed to Audit Committee
Director Jennifer 'Jenny' Johnson appointed to Audit Committee effective September 21, 2023.
Thermo Fisher issues $2.95B senior notes, redeems $1B floating-rate notes
Issued $600M 4.953% notes due 2026, $750M 4.977% notes due 2030, $1B 5.086% notes due 2033, $600M 5.404% notes due 2043.
Thermo Fisher redeems $1B floating-rate notes, prices $2.95B new fixed-rate notes
Redeems $500M floating-rate notes due 2023 and $500M due 2024 on Aug 18 at par plus accrued interest.
Thermo Fisher Q2 revenue $10.69B (-3% YoY), GAAP EPS $3.51, cuts FY guidance
Q2 revenue $10.69B, down 3% YoY; core organic growth +2%; COVID testing revenue $0.08B.
Thermo Fisher elects Franklin Resources CEO Jenny Johnson to Board of Directors
Board increased to 12 members; Jennifer Johnson elected director effective July 13, 2023.
Shareholders approved Amended 2013 Stock Incentive Plan, increasing authorized shares by 7,000,000.
Thermo Fisher Q1 revenue $10.71B (-9% YoY); GAAP EPS $3.32, adjusted EPS $5.03
Revenue $10.71B, down 9% YoY; core organic growth 6%; COVID testing revenue $0.14B.
Thermo Fisher Q4 revenue $11.45B (+7% YoY), adjusted EPS $5.40; FY2023 guidance: rev $45.3B
Q4 revenue $11.45B (+7% YoY); GAAP EPS $4.01 (vs $4.17), adjusted EPS $5.40 (vs $6.54).
Euro offering: €500M 3.200% notes due 2026 and €750M 3.650% notes due 2034; net proceeds ~€1.24B.
Thermo Fisher aligns CEO Marc Casper's equity vesting on retirement with other officers
Compensation Committee amended equity awards for CEO Marc Casper to align retirement vesting with other officers.
Thermo Fisher Q3 revenue $10.68B, GAAP EPS $3.79, adjusted EPS $5.08
Revenue grew 14% to $10.68B; core organic revenue growth 14%.
Thermo Fisher Scientific issues ¥110 billion of senior notes in six tranches
Issued ¥22.3B in 0.853% notes due 2025, ¥28.9B in 1.054% notes due 2027, ¥4.7B in 1.279% notes due 2029.
Thermo Fisher Q2 revenue $10.97B (+18% YoY); GAAP EPS $4.22, adjusted EPS $5.51
Revenue $10.97B (+18% YoY); core organic growth 13%; COVID testing revenue $0.63B.
Thermo Fisher Scientific reports 2022 annual meeting voting results
All 12 director nominees elected; Marc N. Casper received 295.0M for, 28.6M against.
Thermo Fisher Q1 revenue $11.82B (+19%), adjusted EPS $7.25; raises dividend 15%
GAAP EPS $5.61 vs $5.88 last year; adjusted EPS $7.25 vs $7.21.
Board increased to 13; Ruby R. Chandy elected effective March 1, 2022, term through 2022 annual meeting; serve on Audit Committee.
Thermo Fisher Q4 revenue $10.70B, adj EPS $6.54; full-year rev up 22% to $39.21B
Q4 GAAP diluted EPS $4.17 (vs $6.24); adjusted EPS $6.54 (vs $7.09); COVID-19 response rev $2.45B.
Thermo Fisher to redeem $350M 3.650% Senior Notes due 2025 on Feb 7, 2022
$350M aggregate principal of 3.650% Senior Notes due 2025 to be redeemed on February 7, 2022.
Thermo Fisher enters new $5.0B credit facility and expands CP program to $5.0B
New $5.0B unsecured five-year revolving credit facility replaces prior $3.0B facility, matures Jan 7, 2027.
Thermo Fisher redeems $1.2B 2026 and $750M 2027 notes for ~$1.95B
Redeems $1.2B of 2.95% Senior Notes due 2026 and $750M of 3.2% Senior Notes due 2027.
Thermo Fisher completes $17.4B acquisition of clinical research firm PPD, Inc.
Total consideration $17.4 billion; PPD common stock ceased trading on Nasdaq.
increased its size to twelve members and elected Karen S. Lynch as a director of the Company, effective February 19, 2025, for a term expiring at the Company’s 2025 annual meeting.
elected Jennifer “Jenny” Johnson, president and chief executive officer of Franklin Resources, Inc., as a director of the Company, effective July 13, 2023
On February 23, 2022, the Board of Directors of Thermo Fisher Scientific Inc. (the “Company”) increased the size of its board to thirteen members and elected Ruby R. Chandy as a director of the Company for a term expiring at the Company’s 2022 annual meeting, both effective as of March 1, 2022.
Also on February 23, 2022, Thomas J. Lynch, who has served as a director of the Company since 2009, and as Lead Director since 2020, advised the Board that he plans to retire from the Board when his current term as a director expires at the 2022 annual meeting.
Mark Stevenson, Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific Inc. (the “Company”), notified the Company of his decision to retire effective March 18, 2022
the Board of Directors of the Company appointed Gianluca Pettiti, currently Senior Vice President and President of the Company’s Specialty Diagnostics business, Executive Vice President, effective December 27, 2021.
Syed Jafry, Senior Vice President, Regions, notified the Company of his decision to retire effective March 31, 2022.
the Board of Directors of the Company appointed Michel Lagarde, currently Executive Vice President, Executive Vice President and Chief Operating Officer, effective January 1, 2022.
Max materiality 0.85 · Median 0.65 · Most common event earnings